Provided by Tiger Trade Technology Pte. Ltd.

Cardiff Oncology, Inc.

0.9936
+0.05365.70%
Post-market: 1.000.0064+0.64%19:30 EDT
Volume:593.65K
Turnover:563.34K
Market Cap:77.18M
PE:-1.68
High:1.01
Open:0.9401
Low:0.9026
Close:0.9400
52wk High:3.31
52wk Low:0.7566
Shares:77.67M
Float Shares:75.24M
Volume Ratio:0.82
T/O Rate:0.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5914
EPS(LYR):-0.6863
ROE:-94.08%
ROA:-46.73%
PB:2.91
PE(LYR):-1.45

Loading ...

Cardiff Oncology CEO Mani Mohindru acquires 24,703 common shares for $29,890.63

Reuters
·
Jun 22

Cardiff Oncology shareholders approve 2021 equity plan share increase to 15,150,000 shares

Reuters
·
Jun 12

Cardiff Oncology Cut to Hold From Buy by Craig-Hallum

Dow Jones
·
Jun 04

Cardiff Oncology downgraded to Hold from Buy at Craig-Hallum

TIPRANKS
·
Jun 04

Cardiff Oncology announces results from CRDF-004 trial

TIPRANKS
·
Jun 02

BRIEF-Cardiff Oncology Announces Presentation Of Positive Results From Its Randomized, Controlled Phase 2 Trial Of Onvansertib In First-Line RAS-Mutated mCRC At The 2026 ASCO Annual Meeting

Reuters
·
Jun 02

Cardiff Oncology says Phase 2 trial shows 72.2% response rate for onvansertib combo in first-line RAS-mutated mCRC

Reuters
·
Jun 02

Cardiff Oncology - Median Pfs Not Reached in Onvansertib Plus Folfiri/Bevacizumab Arms

THOMSON REUTERS
·
Jun 02

Cardiff Oncology - 30 Mg Onvansertib Plus Folfiri/Bevacizumab Arm Shows Orr of 72.2% VS 42.1% for Soc

THOMSON REUTERS
·
Jun 02

Cardiff Oncology - Onvansertib Safe and Well-Tolerated With No New Toxicities Added to Soc

THOMSON REUTERS
·
Jun 02

Cardiff Oncology Announces Presentation of Positive Results From Its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line Ras-Mutated Mcrc at the 2026 Asco Annual Meeting

THOMSON REUTERS
·
Jun 02

Cardiff Oncology - Phase 2 Trial Achieves Primary Goal Selecting Onvansertib Dose for Registration

THOMSON REUTERS
·
Jun 02

Kazia Therapeutics names James Levine CFO effective June 1

Reuters
·
Jun 02

Cardiff Oncology to present at Jefferies Global Healthcare Conference

Reuters
·
Jun 02

Cardiff Oncology Cut to Neutral From Buy by HC Wainwright & Co.

Dow Jones
·
Jun 01

Cardiff Oncology Inc : H.c. Wainwright Cuts to Neutral From Buy

THOMSON REUTERS
·
Jun 01

HC Wainwright Downgrades Cardiff Oncology to Neutral From Buy

MT Newswires Live
·
Jun 01

U.S. RESEARCH ROUNDUP-Palomar Holdings, Replimune Group, Snowflake

Reuters
·
Jun 01

BRIEF-Cardiff Oncology - Nms Informs Cardiff Oncology Of Agreement Termination On May 27, 2026

Reuters
·
May 30

Cardiff Oncology - Nms Alleges Cardiff Oncology Breached Agreement Over Cardiff Patents Inventorship - SEC Filing

THOMSON REUTERS
·
May 30